Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

REGORAFENIB for Soft tissue neoplasm: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 6 adverse event reports in the FDA FAERS database where REGORAFENIB was used for Soft tissue neoplasm.

Most Reported Side Effects for REGORAFENIB

Side Effect Reports % Deaths Hosp.
Off label use 1,906 20.2% 244 702
Fatigue 1,530 16.2% 168 556
Palmar-plantar erythrodysaesthesia syndrome 1,230 13.0% 201 297
Diarrhoea 1,221 12.9% 174 418
Decreased appetite 941 10.0% 146 408
Asthenia 825 8.7% 159 373
Death 813 8.6% 810 166
Dysphonia 702 7.4% 57 232
Nausea 688 7.3% 86 312
Pain in extremity 686 7.3% 31 197
Pyrexia 626 6.6% 85 422
Hypertension 606 6.4% 77 201
Weight decreased 574 6.1% 82 217
Vomiting 477 5.1% 64 267
Pain 473 5.0% 53 169

Other Indications for REGORAFENIB

Colon cancer (1,699) Colorectal cancer (1,313) Colorectal cancer metastatic (1,234) Hepatocellular carcinoma (1,050) Rectal cancer (505) Gastrointestinal stromal tumour (473) Product used for unknown indication (253) Hepatic cancer (252) Metastases to liver (252) Colon cancer metastatic (205)

Other Drugs Used for Soft tissue neoplasm

PEXIDARTINIB (223) PAZOPANIB (85) VIMSELTINIB (64) NIROGACESTAT (40) IMATINIB (24) NIVOLUMAB (20) CABOZANTINIB S-MALATE (17) SORAFENIB (14) SUNITINIB MALATE (14) CABOZANTINIB (12)

Related Pages

REGORAFENIB Full Profile All Soft tissue neoplasm Drugs REGORAFENIB Demographics REGORAFENIB Timeline